ABVC BIOPHARMA, INC. (ABVC) Financials
Annual revenue, profitability and per-share results for ABVC BIOPHARMA, INC., as reported in SEC filings.
Revenue • FY2025
$296K
▼ 69.5%YoY
Net income • FY2025
-$7.91M
▲ 51.8%YoY
Diluted EPS • FY2025
-$0.39
▲ 22.0%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $296K | -$7.91M | — | -$0.39 | — | -2416.0% | -41.9% |
| FY2022 | $969.8K | -$16.42M | $683.4K | -$0.50 | -$7.52M | -1558.5% | +172.6% |
| FY2021 | $355.8K | -$12.04M | $350.7K | -$0.51 | -$7.62M | -3290.1% | -26.3% |
| FY2020 | $483K | -$10.59M | $464.3K | -$0.50 | — | -1760.9% | -31.2% |
Figures as reported in ABVC BIOPHARMA, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ABVC filing.
Get an email when ABVC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.